Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Paragon Novel Vaccine (PNV) an effective protection against all serotypes of five deadly bacteria to eradicate Antimicrobial Resistance (AMR)

Project description

Multipotent antibacterial vaccine

Antibiotic resistance is an emerging medical problem of global significance, threatening the treatment of bacterial infections using conventional drugs. Funded by the European Innovation Council, the PARAGON NOVEL VACCINE project has developed a novel immunotherapy that targets glyeraldehyde-3-phosphate dehydrogenase (GAPDH), a protein that suppresses host immunity by inducing an early production of interleukin-10, a potent anti-inflammatory cytokine. It is a peptide-based vaccine that blocks the bacterial GAPDH without interfering with the human analogue and treats infection from all invasive serotypes of five different bacterial strains. The project aims to further develop and test the innovative vaccine following promising preclinical data.

Objective

Immunethep has developed, patented (WO/2015/189422), and successfully undergone preclinical trials for a new breakthrough vaccine (PNV-Paragon Novel Vaccine). It protects against bacterial infections caused by 5 different bacteria: S. aureus, S. pneumoniae, K. pneumoniae, E. coli and GBS. Our innovation relies on the discovery of a virulence and immunosuppressive mechanism common to these pathogens. The bacteria excrete a highly immunosuppressive protein designated as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which disables the host immune response to infection. PNV works by blocking bacterial GAPDH, while not reacting to human GAPDH, allowing the host immune system to fight infection and eliminate the bacteria. Preclinical trials demonstrated high levels of efficacy against any of the 5 bacteria with an excellent safety profile. PNV is the worlds first vaccine not only to prevent multiple bacterial infections but for all invasive serotypes, including multi-resistant strains.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project's classification has been validated by the project's team.

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

IMMUNETHEP
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 499 999,99
Address
BIOCANT PARK, NUCLEO 4 LOTE 3
3060 197 Cantanhede
Portugal

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 7 400 192,50
My booklet 0 0